FindTrial
Sign In

Simvastatin treatment inhibit monocyte chemotactic protein-1 (MCP-1) gene in endometriosis

A prospective study of simvastatin treatment inhibit monocyte chemotactic protein-1 (MCP-1) gene expression in endometriosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20130627003
Enrollment
Unknown
Registered
2013-06-27
Start date
2013-06-27
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis endometriosis MCP&#45

Interventions

Simvastatin 20 mg/d will be prescribed to the subjects 2 weeks before surgery,No medication will be prescribed
Experimental Drug,No Intervention Dietary Supplement
Simvastatin,Control

Sponsors

Ramathibodi hospital
Lead Sponsor
Ramathibodi hospital
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Diagnosed endometriosis patient and need laparoscopic surgery willing to participate Not on Statin medication Never treated with GnRH agonist Never treated with DMPA No contraindication for simvastatin; abnormal liver function test

Exclusion criteria

Exclusion criteria: Participants have side effects from medication such as myalgia, nausea, vomiting, diarrhea Participants deny or withdraw

Design outcomes

Primary

MeasureTime frame
serum MCP-1 8 moths ELISA—

Secondary

MeasureTime frame
endometriotic tissue MCP-1 8 months gene expression by real time PCR—

Countries

Thailand

Contacts

Public ContactSompoj Poomipichet

Mahidol University

somphochp11@hotmail.co.th(662)2011412

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026